#### **GILEAD SCIENCES INC**

Form 4

January 20, 2015

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

2 Jaguar Nama and Tiakar or Trading

OMB Number:

3235-0287

Expires:

5 Relationship of Reporting Person(s) to

January 31, 2005

0.5

Estimated average

**OMB APPROVAL** 

burden hours per response...

subject to Section 16. Form 4 or Form 5 obligations

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \*

01/15/2015

01/15/2015

01/15/2015

Stock

Stock

Stock

Common

Common

BISCHOFBERGER NORBERT W			Symbol GILEAD SCIENCES INC [GILD]					Is	Issuer			
(Last) (First) (Middle)  GILEAD SCIENCES, INC., 333  LAKESIDE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 01/15/2015					(Check all applicable)  Director 10% OwnerX_ Officer (give title Other (specify below)  EVP, R&D and CSO				
		(Street)		4. If Am Filed(Mo			ate Origina	ıl	A	Individual or Join pplicable Line) K_ Form filed by On	e Reporting Per	son
	FOSTER C	CITY, CA 94404							Pe	_ Form filed by Mo erson	re than One Rep	oorting
	(City)	(State)	(Zip)	Tab	le I - No	n-l	Derivative	Secui	rities Acquir	ed, Disposed of,	or Beneficiall	y Owned
	1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transac Code (Instr. 8	3)	4. Securition Dispose (Instr. 3, 4)	ed of (		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
	Common Stock	01/15/2015			M		70,000	A	\$ 16.395	189,302	D	
	Common	01/15/2015			S		32 1/12	D	\$ 07.8123	157 160	D	

32,142 D

26,179 D

11,679 D

97.8123

98.7731

(3) \$

(4)

\$

(5)

157,160

130,981

99.6163 119,302

D

D

D

S

S

S

#### Edgar Filing: GILEAD SCIENCES INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4,		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right to buy)	\$ 16.395	01/15/2015		M(1)	70,000	(2)	01/22/2017	Common Stock	70,0

Dalatianshin

## **Reporting Owners**

Reporting Owner Name / Address	Keiationsinps						
	Director	10% Owner	Officer	Other			

BISCHOFBERGER NORBERT W GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404

EVP, R&D and CSO

# **Signatures**

/s/ Norbert W.
Bischofberger 01/19/2015

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- (2) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (3) Sale prices reported for the transactions reported here range from \$97.27 to \$98.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (4) Sale prices reported for the transactions reported here range from \$98.27 to \$99.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request

Reporting Owners 2

### Edgar Filing: GILEAD SCIENCES INC - Form 4

(5) Sale prices reported for the transactions reported here range from \$99.27 to \$100.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.